The stock of the Danish pharmaceutical company Novo Nordisk is falling sharply on the Copenhagen Stock Exchange, down over 6 percent, following a presentation of a study on the effects of the weight loss preparation Cagrisema.
According to the study, Cagrisema provided a good weight loss for adults with obesity or overweight with type 2 diabetes.
Over 68 weeks, those who took the preparation lost 15.7 percent in weight, which can be compared to 3.1 percent with placebo treatment.
The details from the study will be presented at a scientific conference this year, announces Novo Nordisk.
